July 18, 2022
Bernadett S et al. European Urology, 2022
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
You might also be interested by
Posters
Development of a visual scoring method to determine inflamed, excluded or desert immune phenotype in Non-Small Cell Lung Cancer, Colorectal Cancer, and Urothelial Cancer
November 7, 2024
Histopathology
More infoBrochures & Infographics
Immunohistochemistry (IHC) Biomarker List
October 10, 2024
Histopathology
More infoCellTalk Blog
Optimal FFPE Tissue Fixation, Processing, and Embedding: A Comprehensive Guide
September 4, 2024
Histopathology
More infoCellTalk Blog
Optimizing your in situ hybridization for success
August 30, 2024
Histopathology
More info